Drug intelligence / Profile preview

Oralgen

Development stage: Phase 4
Lead developer: ALK Abelló
Modality: Vaccines & Immunotherapeutics
Administration: Sublingual

Overview

Oralgen is a sublingual immunotherapy developed by Artu Biologicals, containing grass pollen extract. It is indicated for the treatment of grass pollen related allergic rhinoconjunctivitis, aiming to induce immune tolerance to grass pollen allergens and reduce allergic symptoms.

Beyond the preview

Go deeper on Oralgen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oralgen.

Explore the full profile